JP2020523406A - 眼科用組成物および使用方法 - Google Patents

眼科用組成物および使用方法 Download PDF

Info

Publication number
JP2020523406A
JP2020523406A JP2020514657A JP2020514657A JP2020523406A JP 2020523406 A JP2020523406 A JP 2020523406A JP 2020514657 A JP2020514657 A JP 2020514657A JP 2020514657 A JP2020514657 A JP 2020514657A JP 2020523406 A JP2020523406 A JP 2020523406A
Authority
JP
Japan
Prior art keywords
composition
ophthalmic
pharmaceutically acceptable
dry eye
ocular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020514657A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020523406A5 (OSRAM
Inventor
ムスヌリ，シャンカル
ジェイン，サンディープ
アルムガム，ラサッパ
，アルン ウパデアーエ
，アルン ウパデアーエ
ナデル，マシュー
ソマセカル，ゴパラム
Original Assignee
オクジェン アイエヌシー．
オクジェン アイエヌシー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オクジェン アイエヌシー．, オクジェン アイエヌシー． filed Critical オクジェン アイエヌシー．
Publication of JP2020523406A publication Critical patent/JP2020523406A/ja
Publication of JP2020523406A5 publication Critical patent/JP2020523406A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2020514657A 2017-05-19 2018-04-05 眼科用組成物および使用方法 Pending JP2020523406A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762509015P 2017-05-19 2017-05-19
US62/509,015 2017-05-19
US201762591548P 2017-11-28 2017-11-28
US62/591,548 2017-11-28
PCT/US2018/026342 WO2018212846A1 (en) 2017-05-19 2018-04-05 Ophthalmic compositions and methods of use

Publications (2)

Publication Number Publication Date
JP2020523406A true JP2020523406A (ja) 2020-08-06
JP2020523406A5 JP2020523406A5 (OSRAM) 2021-05-13

Family

ID=64269595

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020514657A Pending JP2020523406A (ja) 2017-05-19 2018-04-05 眼科用組成物および使用方法

Country Status (5)

Country Link
US (1) US10555947B2 (OSRAM)
EP (1) EP3624773A4 (OSRAM)
JP (1) JP2020523406A (OSRAM)
CN (1) CN110996904A (OSRAM)
WO (2) WO2018212846A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023546452A (ja) * 2020-10-21 2023-11-02 アズーラ オフサルミックス エルティーディー． 眼障害を処置するための化合物および方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019060696A1 (en) 2017-09-25 2019-03-28 Surface Pharmaceuticals, Inc. OPTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR SURFACE DISEASE
US20230277557A1 (en) * 2017-09-25 2023-09-07 Surface Ophthalmics, Inc. Pharmaceutical kits and their use for treating dry eye disease
US12144855B2 (en) 2018-04-30 2024-11-19 Merck Sharp & Dohme Llc Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres
JP7397000B2 (ja) 2018-04-30 2023-12-12 メルク・シャープ・アンド・ドーム・エルエルシー 凍結乾燥変異ジフテリア毒素のジメチルスルホキシド中均一溶液を提供する方法
US11077053B2 (en) 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
CN113473970A (zh) 2018-12-27 2021-10-01 瑟菲斯眼科股份有限公司 用以治疗眼表疾病的眼科药物组合物和方法
EP3705114A1 (en) * 2019-03-06 2020-09-09 Avizorex Pharma, S.L. Ophthalmic composition for treating dry eye and symptoms thereof
RU2705392C1 (ru) * 2019-07-19 2019-11-07 федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Глазная мазь на основе 6-метил-3-(тиетан-3-ил)урацила с ранозаживляющим эффектом
WO2021191273A1 (en) 2020-03-24 2021-09-30 Hovione Scientia Limited Compositions for use in treating meibomian gland dysfunction
JP2024505517A (ja) * 2021-01-28 2024-02-06 グラウコス コーポレイション 製剤
US12440510B2 (en) 2021-05-10 2025-10-14 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
WO2022240598A1 (en) 2021-05-10 2022-11-17 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
US11672798B2 (en) * 2021-06-03 2023-06-13 Laboratorios Salvat, S.A. Ciprofloxacin ophthalmic topical composition for treating ocular disease
KR102391198B1 (ko) * 2021-08-27 2022-04-27 한림제약(주) 리피테그라스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 수용액 형태의 점안액 조성물
IL313616A (en) 2021-12-17 2024-08-01 Aerie Pharmaceuticals Inc Ophthalmic pharmaceutical compositions and uses thereof
WO2023152644A1 (en) * 2022-02-08 2023-08-17 Orbicular Pharmaceutical Technologies Pvt. Ltd Pharmaceutical composition of lifitegrast and loteprednol etabonate
WO2024028816A1 (en) * 2022-08-04 2024-02-08 Bausch + Lomb Ireland Limited Ophthalmic composition comprising pilocarpine and a redness reduction agent
US20240041869A1 (en) * 2022-08-04 2024-02-08 Bausch + Lomb Ireland Limited Ophthalmic composition comprising an anti-allergen and a redness reduction agent
CN115645356A (zh) * 2022-11-21 2023-01-31 山东诺明康药物研究院有限公司 一种酒石酸溴莫尼定原位凝胶及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007505155A (ja) * 2003-05-12 2007-03-08 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー ビトロネクチンレセプタ・アンタゴニスト化合物および放射性薬品製造におけるその使用
JP2007509952A (ja) * 2003-10-31 2007-04-19 ボーシュ アンド ローム インコーポレイティド ロテプレドノールエタボネートおよびトブラマイシンの局所眼科用懸濁液
WO2016138049A1 (en) * 2015-02-24 2016-09-01 The Board Of Trustees Of The University Of Illinois Methods and compositions for treating dry eye disease and other eye disorders
WO2017006272A1 (en) * 2015-07-08 2017-01-12 Glaxosmithkline Intellectual Property Limited Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2142103C (en) * 1992-08-28 2003-07-08 Haim Aviv Submicron emulsions as ocular drug delivery vehicles
WO2000023023A1 (en) * 1998-10-20 2000-04-27 The University Of North Carolina At Chapel Hill Methods of hydrating mucosal surfaces
US20050196370A1 (en) 2003-03-18 2005-09-08 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
US20050182039A1 (en) * 2004-02-13 2005-08-18 Bausch & Lomb Incorporated Use of Loteprednol etabonate for the treatment of dry eye
WO2006004577A2 (en) 2004-03-12 2006-01-12 Melbj Holdings, Llc Lubricant for the ocular surface
MXPA06010849A (es) * 2004-03-25 2007-03-08 Bausch & Lomb Uso de loteprednol etabonato para el tratamiento del ojo seco.
AR062046A1 (es) 2006-07-25 2008-08-10 Osmotica Pharmaceutical Argentina S A Soluciones oftalmicas
TWM353756U (en) * 2008-04-24 2009-04-01 zong-ren Chen Structure of treadmill
US20120003296A1 (en) 2010-07-01 2012-01-05 Shantha Totada R New methods of treating dry eye syndrome
EP2605771B1 (en) 2010-08-16 2018-04-04 Allergan, Inc. Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists
US20120076738A1 (en) 2010-09-28 2012-03-29 Michael Graeber Combination treatment for dermatological conditions
US20120093876A1 (en) 2010-10-13 2012-04-19 Aciex, Inc. Ophthalmic Formulations, Methods Of Manufacture And Methods of Normalizing Meibomian Gland Secretions
KR102165246B1 (ko) 2011-04-05 2020-10-13 옵토솔브 리서치 앤드 디벨롭먼트 리미티드 안과 치료제
EP2630952A1 (en) 2012-02-23 2013-08-28 Novagali Pharma S.A. Self-preserved oil dispersions comprising boric acid
JP6197386B2 (ja) * 2012-06-08 2017-09-20 ライオン株式会社 ナノエマルション粒子を含む組成物及びその製造方法
KR20160146669A (ko) * 2014-02-14 2016-12-21 징준 후앙 나노에멀젼 전달 시스템의 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007505155A (ja) * 2003-05-12 2007-03-08 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー ビトロネクチンレセプタ・アンタゴニスト化合物および放射性薬品製造におけるその使用
JP2007509952A (ja) * 2003-10-31 2007-04-19 ボーシュ アンド ローム インコーポレイティド ロテプレドノールエタボネートおよびトブラマイシンの局所眼科用懸濁液
WO2016138049A1 (en) * 2015-02-24 2016-09-01 The Board Of Trustees Of The University Of Illinois Methods and compositions for treating dry eye disease and other eye disorders
WO2017006272A1 (en) * 2015-07-08 2017-01-12 Glaxosmithkline Intellectual Property Limited Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OPHTHALMOLOGY, vol. 121, no. 2, JPN6022013177, 2014, pages 475 - 483, ISSN: 0005002649 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023546452A (ja) * 2020-10-21 2023-11-02 アズーラ オフサルミックス エルティーディー． 眼障害を処置するための化合物および方法

Also Published As

Publication number Publication date
EP3624773A4 (en) 2021-04-07
WO2018212846A1 (en) 2018-11-22
US20180333414A1 (en) 2018-11-22
WO2018212955A1 (en) 2018-11-22
EP3624773A1 (en) 2020-03-25
US10555947B2 (en) 2020-02-11
CN110996904A (zh) 2020-04-10

Similar Documents

Publication Publication Date Title
US10555947B2 (en) Ophthalmic compositions and methods of use
US20230037486A1 (en) Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery
US9597328B2 (en) Methods and compositions for treating dry eye disease and other eye disorders
US20190008920A1 (en) Ophthalmic compositions and methods of use
US20200197410A1 (en) D2o stabilized pharmaceutical formulations
JP6704400B2 (ja) 眼科用液剤
US11759472B2 (en) Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
KR20100072333A (ko) 약물 전달을 위한 비히클로서의 비-수성 수혼화성 물질
JP7796783B2 (ja) 眼周囲分泌腺におけるまたは眼表面での異常な炎症を処置するための組成物および使用方法
AU2024220033B2 (en) Liquid depot for non-invasive sustained delivery of agents to the eye
JP2025513090A (ja) 眼疾患の治療のためのミコフェノール酸及び／又はベタメタゾンの医薬組成物
WO2017179003A1 (en) Topical compositions for ophthalmic and otic use
US10751337B2 (en) Preservative free ocular compositions and methods for using the same for treating dry eye disease and other eye disorders
WO2020047197A1 (en) Ophthalmic compositions and methods of use
WO2021240376A2 (en) Ophthalmic nanoemulsion compositions
US20180333357A1 (en) Nanoemulsions with anti-inflammatory activity
WO2020240451A1 (en) In-situ gelling nanoemulsion of brinzolamide
CA3115664C (en) Ophthalmic compositions and methods of use
US20180221278A1 (en) Prsustained release opthalmic formuation and methods for using the same
US20230158045A1 (en) Pharmaceutical compositions of mycophenolic acid and/or betamethasone for the treatment of ocular disorders
WO2023152644A1 (en) Pharmaceutical composition of lifitegrast and loteprednol etabonate
US9877964B2 (en) Methods and compositions for treating dry eye disease and other eye disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210331

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220804

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230301